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Abstract 
This review provides an overview of metal-based anticancer drugs and drug candidates. 
In particular, we focus on metal complexes that can be activated in the reducing envi-
ronment of cancer cells, thus serving as prodrugs. There are many reports of Pt and Ru 
complexes as redox-activatable drug candidates, but other d-block elements with vari-
able oxidation states have a similar potential to serve as prodrugs in this manner. In this 
context are compounds based on Fe, Co, or Cu chemistry, which are also covered. A 
trend in the field of medicinal inorganic chemistry has been toward molecularly targeted, 
metal-based drugs obtained by functionalizing complexes with biologically active 
ligands. Another recent activity is the use of nanomaterials for drug delivery, exploiting 
passive targeting of tumors with nano-sized constructs made from Au, Fe, carbon, or 
organic polymers. Although complexes of all of the above mentioned metals will be de-
scribed, this review focuses primarily on Pt compounds, including constructs containing 
nanomaterials. 
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1. Introduction 
Most drugs are organic or biologically derived compounds, and the pharmaceutical in-
dustry focuses on organic chemistry with some exceptions [1]. Metal-based therapeu-
tics comprise only a small percentage of available drugs. After the discovery and suc-
cessful clinical applications of the Pt-based anticancer drug cisplatin, however, research 
on metal-based drugs became increasingly more important. There is a growing interest 
in metal-containing drugs, and medicinal inorganic chemistry covering applications of 
metals in therapeutics and diagnostics is a field of increasing prominence [2]. The major 
advantage of metal-based over organic-based drugs is the ability to vary coordination 
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number, geometry, and redox states. Metals can also change the pharmacological 
properties of organic-based drugs by forming coordination complexes with them [1]. 
Cisplatin is one of the most widely used anticancer drugs, administered particularly for 
ovarian and testicular cancer. If testicular tumors are discovered early, an impressive 
cure rate of almost 100% is achieved. Significant side-effects due to systemic toxicity 
include nausea, bone-marrow suppression, and nephrotoxicity. Drug resistance, inher-
ent or acquired, also poses a great problem [3]. In an effort to diminish side effects and 
resistance caused by cisplatin, other metal-based drugs are being investigated. 
Metal-based pharmaceuticals can be arranged into seven categories depending on the 
function of the metal and ligand moieties according to Hambley et al. [4]: 1) the metal 
complex is active in its inert form, 2) the metal complex is active in its reactive form, 3) 
the metal serves as a radiation enhancer, 4) the compound contains a radioactive 
metal, 5) the metal or its biotransformation product is active, 6) a ligand is biologically 
active, and 7) only a fragment of the complex is active. The two latter categories apply 
to compounds presented in this review and represent two major strategies explored for 
the design of metal-containing drugs: targeting and prodrug concept. The targeting 
strategy uses selective transport of functionalized drug molecules recognized by recep-
tors highly or only expressed on the surface of cancer cells. The prodrug strategy com-
prises the delivery of a cytotoxic compound that is only activated under conditions pre-
sent in the targeted tissue or cells. Deactivation by cellular components before reaching 
the target would ideally be inhibited in the prodrug form. Triggers for prodrug activation 
can be pH, light or the redox environment. When compared to organic molecules, ac-
cess to redox chemistry is a clear advantage of metal-containing compounds, since 
they generally have biologically accessible redox potentials. Accordingly, among the 
different strategies for releasing metal-containing fragments from prodrugs, the most 
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successful is redox activation, in which the active species is formed in a reductive cellu-
lar environment [5]. 
Tumors are characterized by low oxygen concentration levels which give rise to a more 
reducing environment compared to normal tissue. The reductive microenvironment of 
hypoxic tumors results from insufficient formation of new blood vessels during growth 
[6]. Also, a large concentration of cellular reducing agents like glutathione is present in 
cancer cells, contributing to a reductive environment. Tumor hypoxia has been linked to 
unsuccessful treatments using chemotherapy and radiotherapy due to distance from 
blood vessels and resulting low oxygen levels [7]. Tumor cells that can survive in hy-
poxic conditions upregulate drug resistance genes [8]. Although hypoxia is considered a 
serious problem in cancer therapy, it can be exploited for therapeutic selectivity, since it 
differentiates cancerous and healthy tissue. One promising avenue is the development 
of bioreductive drugs that are selectively activated under such intracellular conditions. 
Literature known bioreductively activatable agents comprise quinones, nitroimidazoles, 
aromatic N-oxides, mustard nitrogens, and a few metal-containing compounds [8, 9]. 
Metal compounds are to be delivered to the target environment in an inert oxidized state  
(without prior reduction), and metabolized when they reach the reductive environment of 
the cancer cell rendering the inactive compound cytotoxic. Three Pt(IV) and two Ru(III) 
compounds have already been in clinical trials – to date the most promising bioreduc-
tive pharmaceuticals based on metals [6]. 
This review covers applications of metal-based drugs for anticancer applications using 
the redox-activated prodrug strategy. Electrochemical aspects of redox-activatable Pt 
and, particularly, Ru compounds have been reviewed in detail recently [6]. Thus, this 
review focuses on literature that has been published since then and electrochemical 
aspects will be touched only superficially. 
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 2. Platinum 
Cisplatin (1, Figure 1), one of the most successful anticancer drugs, and its analogs 
carboplatin and oxaliplatin (2, 3) are currently in routine clinical use worldwide. Pt anti-
cancer agents only approved in Asia include nedaplatin, lobaplatin, and heptaplatin (4-
6). 
 
Figure 1. Pt-based drugs in worldwide clinical use: cis- (1), carbo- (2), and oxaliplatin 
(3), and clinical use only in some Asian countries: neda- (4), loba- (5) and heptaplatin 
(6). 
 
Once in the cell, where the chloride concentration drops from about 100 mM in extracel-
lular fluids to 4 mM, cisplatin is aquated by substitution of its chlorido ligands with water 
ligands. Only 1% (or less) of the administered cisplatin ends up binding to the biological 
target DNA, which results in apoptotic cell death. The majority of cisplatin reacts with 
proteins and low molecular weight biomolecules, especially with those containing sulfur. 
This non-discriminate binding causes side-effects of cisplatin like nephrotoxicity [3]. 
Carboplatin (2) displays a more tolerable toxicological profile due to the higher stability 
of the chelating 1,1-cyclobutanedicarboxylato ligand when compared to the chlorido 
ligands in cisplatin. No nephrotoxicity is observed [10]. Oxaliplatin (3) is also active 
against cancer cell lines that are resistant to cisplatin and carboplatin [10]. 
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Clinical complications associated with the use of cisplatin, such as nephro- and neuro-
toxicity and the fact that only some tumors can be cured, might be overcome by using 
prodrugs with platinum in the more inert +IV oxidation state (Scheme 1) [2]. The admini-
stration of non-toxic Pt(IV) prodrugs that can be activated selectively by reduction at the 
tumor sites might reduce unwanted reactions with biomolecules and thus minimize un-
desired side-effects. Even oral administration is conceivable, since in contrast to the 
quite reactive Pt(II), Pt(IV) compounds are more stable in biological fluids. Degradation 
in the gastrointestinal tract is thus less likely, and the Pt(IV) prodrugs may reach the 
cellular target without prior transformation. 
 
 
Scheme 1. Activation by reduction: A Pt(IV) prodrug carrying axial ligands L, ammine 
ligands NH3, and chlorido ligands Cl– in the equatorial positions yields cisplatin (1) upon 
reduction accompanied by the loss of both axial ligands. Most probably, a Pt(II) species 
then binds to nuclear DNA. 
 
Pt(IV) has a low-spin d6 electron configuration and exhibits octahedral geometry. This 
configuration is relatively inert to substitution; reactions with biological nucleophiles are 
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thus disfavored compared to Pt(II) complexes, and the lifetime in biological fluids is ex-
pected to increase. It is not yet established, however, that Pt(IV) complexes survive 
long enough in vivo to be delivered to the tumor sites. The platinum compound could be 
also reduced extracellularly and enter the cell as Pt(II) (Scheme 1). As investigated by 
XANES (X-ray absorption near edge structure) analyses, the cellular distribution of 
Pt(IV) compounds 24 h after exposure is indeed similar to that of cisplatin. This result 
may indicate that the compound is readily reduced over that time period [11]. Micro-
probe SRIXE (synchrotron radiation-induced X-ray emission) is another excellent 
method for evaluating Pt compounds in whole and sectioned cells. This method has 
provided valuable insights into the distribution patterns and oxidation states of Pt drugs 
in cells [12]. 
Variation of the axial ligands in Pt(IV) complexes affords a valuable strategy for altering 
their lipophilicity and redox potentials, factors that may affect the ability to enter tumor 
cells before being reduced to the active Pt(II) compound and, subsequently, the cytotox-
icity. For a series of different Pt(IV) complexes which, upon reduction, yield the same 
Pt(II) species there was an 800-fold range in cytotoxicity [13]. Although the pharmacol-
ogy of Pt(IV) compounds seems to depend strongly on the nature of the axial ligands, 
activity can be also influenced by the potency of the Pt(II) complex formed upon reduc-
tion [14]. 
Lipophilic drugs are supposed to diffuse readily through cell membranes, thereby in-
creasing their uptake. Lipophilicity, however, has to fall within an optimal window, oth-
erwise the complex either becomes too insoluble in aqueous media or is trapped within 
the membrane. Platinum compounds with intermediate lipophilicity are therefore 
advantageous for cell uptake and anticancer activity [15]. 
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More electronegative ligands tend to destabilize Pt(IV) compounds. Most easily reduced 
are those having axial chlorido ligands, and the most difficult are compounds with hy-
droxido ligands [10, 16]. The latter (L=OH) have reduction potentials that fall in the -900 
mV range vs. Ag/AgCl in Pt(IV) complexes cis,trans,cis-[PtCl2L2(en)] and -
[PtCl2L2(NH3)2], whereas analogous complexes with axial chlorido ligands (L=Cl) have 
reduction potentials of ~ -250 mV vs. Ag/AgCl. Related complexes carrying axial ace-
tato ligands fall in between, with reduction potentials ~ -600 mV vs. Ag/AgCl [15, 17-19]. 
The reduction potential becomes more positive for bulkier carboxylate ligands (propion-
ate, butyrate) [18]. For complexes of formula cis,trans,cis-|PtCl2L2(NH3)2], the net elec-
tron donor character correlates well with reduction rates and redox potentials in the ax-
ial ligand order L = OH– < alkylCOO– < Cl– < CF3COO– [17]. 
Potential reducing agents for Pt(IV) in the cell are glutathione [20-22], for which  
E0 = -240 mV at pH 7.0 [23], ascorbate (vitamin C), NAD(P)H, and cysteine-containing 
proteins [14, 24]. Metallothionein, a protein consisting of 61 amino acids with 20 cys-
teine residues, is a potential binding and redox partner for Pt(IV). Increased metal-
lothionein levels are proposed as a mechanism by which cells become resistant to 
platinum drugs [25]. Serum albumin, a small protein with a 35% cysteine content, also 
represents a potential binding partner for cisplatin as well as Pt(IV) compounds [19]. 
Although Pt(IV) can be reduced by both extra- and intracellular reducing agents 
(Scheme 1), higher concentrations of these species are present within cells; e.g., for 
glutathione, the levels are 1-10 mM in cells vs. 2 µM in plasma [26]. Besides reducing 
Pt(IV) complexes efficiently, thiols at high concentrations can also coordinate to and 
deactivate the resulting Pt(II) species, thereby reducing their efficacy. 
The DNA binding properties of Pt complexes of the type cis,trans,cis-[PtCl2L2(en)] corre-
late well with the reduction potentials; the more readily reduced complexes are better 
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able to bind DNA [18]. Although reduction seems to be required for activity, and reactiv-
ity is enhanced in the presence of reducing agents [22, 27], Pt(IV) complexes can ap-
parently also bind directly to DNA (Scheme 1) [28-30]. Reduction of Pt(IV) has even 
been claimed to occur by DNA itself, either by the nucleobases or the sugars of the 
sugar-phosphate backbone [14]. Upon arrival at the target site, the kinetic preference of 
a Pt(IV) complex for reduction by, versus binding to, DNA is then the deciding factor 
[14]. These arguments, while intriguing, would benefit by isolation and identification of 
the DNA fragments that are oxidized in the process. 
Correlations of Pt(IV)/Pt(II) redox potentials with biological activity have been explored 
within the context of quantitative structure-activity relationships (QSAR). Several Pt(IV) 
complexes with various equatorial and axial ligands were synthesized to develop a pre-
dictive QSAR model. Theoretical descriptors were included in this model together with 
physicochemical data like lipophilicity, reduction peak potential, and the number of oxy-
gen atoms in the molecular formula of the ligand [31]. In vitro cytotoxicity could be pre-
dicted based on this QSAR model, but the actual effects in vivo still have to be verified, 
because others have not been able to correlate reduction potential with cytotoxicity 
across a large series of different Pt(IV) complexes [32]. 
The effects of axial and carrier ligands on the reduction potential and cytotoxic proper-
ties of Pt(IV) complexes have also been investigated to define a relationship between 
reduction rate, redox potential, and in vitro cytotoxicity of Pt(IV) compounds. The reduc-
tion rates depended on the electronegativity and the steric hindrance of the axial and 
carrier ligands. Complexes carrying bulkier and more electron-withdrawing ligands were 
reduced more rapidly and showed higher reduction potentials. Reduction rates and the 
cytotoxicity of complexes with different carrier or axial ligands were correlated [17]. 
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As can be concluded from the above examples and other factors, the selection of drug 
candidates based on in vitro activity can be misleading. The most active species is usu-
ally chosen for animal studies, whereas the most inert species in vitro might actually 
show the highest activity in vivo [4]. It is therefore important that the Pt(II) species de-
rived from a Pt(IV) precursor have proven in vivo activity. The effects of simulated hy-
poxia and the use of models like spheroids, which mimic the tumor microenvironment, 
have been examined to predict the behavior of compounds in solid tumors. For exam-
ple, a spheroid-based tumor model revealed that Pt(IV) complexes, although active, 
were unable to display selectivity for hypoxic cells [33]. 
In octahedral Pt(IV) complexes, the two additional ligands are not only valuable for 
modifying solubility in biological media and tuning the redox potential, but they can also 
provide targeting functionalities. Modifications at the axial sites offer the advantage of 
selectivity against cancerous tissue. This feature complements the potential for Pt(IV) 
complexes to be administered orally due to greater stability in the gastrointestinal tract 
as well as their potentially lower side effects due to their greater kinetic inertness com-
pared to Pt(II) compounds. Targeting, directing a Pt(IV) complex to tumor cells and/or a 
subcellular target therein, can be accompanied by attachment of a membrane receptor 
substrate to an axial ligand or, alternatively, by release of therapeutically active axial 
ligands following reduction to Pt(II) in the cancer cell. 
For targeting estrogen-receptor positive (ER(+)) cancers like breast and ovarian, estra-
diol-tethered Pt(IV) complexes have been employed (7, Figure 2, targeting groups are 
depicted in blue). Reduction of the Pt(IV) complex in the intracellular environment re-
leases cisplatin and two equivalents of estradiol. The latter can upregulate expression 
of the protein HMGB1, which can prevent repair of cisplatin-damaged DNA by shielding 
the platinated DNA from the excision repair machinery [34]. Such upregulation of 
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HMGB1 has the potential to sensitize cells to cisplatin. Cytotoxicity in ER(+) cells in-
creased by up to 2-fold when compared to ER(-) cells [35]. 
For overcoming drug resistance, ethacrynic acid was coupled in another Pt(IV) con-
struct termed ethacraplatin (8). The cytosolic enzyme glutathione-S-transferase (GST) 
was inhibited by the two equivalents ethacrynic acid released per Pt(IV) upon reduction. 
In three out of four cell lines the cytotoxicity was increased. After short incubation times 
(24 h) ethacraplatin was up to 2.5 times more effective than cisplatin as measured by 
IC50 values, whereas after 72 h both compounds displayed comparable cytotoxicity [36]. 
 
 
Figure 2. Pt(IV) compounds with bioactive ligands (in blue, 7-11): estrogen-tethered 
Pt(IV) complex (7, n=1-5), ethacraplatin (8), mitaplatin (9), peptide tethered Pt(IV) (10, 
R1 = RGD, NGR, c(CRGDC), c(RGDfK)), platinacyclobutane (11, L = pyridine for R2 = 
thymidine, proline, and L = 2,2’-bipyridine for R2 = glucose, cholesterol). Tetra- (12), 
ipro- (13), satraplatin (14), LA-12 (15), cis,cis,trans-[PtCl2(NH3)(NH2R3)(OOCCH3)2] (16, 
R3 = H, isopropyl, cyclohexyl), [PtCl4(R42eddp)] (17, R4 = ethyl, n-propyl). 
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In pursuit of a similar prodrug strategy, the Pt(IV) compound mitaplatin, cis,cis,trans-
[PtCl2(NH3)2(OOCCHCl2)2] (9), was prepared. Mitaplatin combines the orphan drug di-
chloroacetate (DCA) with cisplatin. DCA alters the mitochondrial membrane potential 
gradient in cancer but not normal cells. As a consequence, cytochrome c is released 
and apoptosis inducing factor is translocated to the nucleus [37]. Mitaplatin can thus 
efficiently target both nuclear DNA with released cisplatin and mitochondria with re-
leased DCA in cancer cells. The cytotoxicity of mitaplatin equals or exceeds that of 
most other Pt(IV) compounds and is comparable to that of cisplatin in a variety of can-
cer cell lines [38]. 
Small peptides recognizable by cancer tissue-specific receptors, the integrins, have 
also been used as targeting moieties. In order to target cells expressing integrins on 
their surface, Pt(IV) was coupled to several small peptides (3-5 amino acids) containing 
RGD or NGR by either one or two amide linkages through either one or two succinato 
groups (10, R1 = RGD, NGR, c(CRGDC), c(RGDfK)) [39]. Cytotoxicity was tested in 
several endothelial and human cancer cells. RGD-tethered Pt(IV) complexes were more 
cytotoxic than non-targeting Pt(IV) compounds and RGD tri- and pentapeptide moieties 
alone. NGR conjugates were less inhibitory than RGD counterparts, but were still more 
active than nonspecific Pt(IV)-peptide analogues. 
Platinacyclobutane complexes (11), in which biologically relevant molecules like 
thymidine, cholesterol, glucose, and proline (R2), are linked to cyclobutane moiety in an 
equatorial position, have also been synthesized. The biocomponents were coupled to 
cyclopropylmethanol and then allowed to react with Zeise’s dimer ([Pt(C2H4)Cl2]2) result-
ing in platinacycles. It is anticipated that the presence of the biomolecules would lead to 
increased water solubility and cancer targeting, but thus far there has been no evalua-
tion of these compounds either in vitro or in vivo [40, 41]. 
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Pt(IV) compounds lacking biologically active ligands have also been quite successful in 
vitro. Four such octahedrally coordinated Pt(IV) complexes have even entered clinical 
trials, namely, tetra- (12), ipro- (13) and satraplatin (14, formerly JM-216, diacetatoam-
minedichlorido(cyclohexylamine)platinum(IV)) as well as LA-12 (15). LA-12, however, 
failed in phase I. Tetraplatin could not be investigated further after phase I studies due 
to its high neurotoxicity. Iproplatin showed only limited success in phase II due to its low 
reactivity. Satraplatin, the first orally available Pt-based drug candidate, had to be 
abandoned recently in phase III [42]. Thus none of the platinum(IV) compounds has yet 
found its way to the clinics because of lower efficacy than cisplatin, variability in drug 
uptake, or the production of severe side-effects [6]. Satraplatin, although failing to pro-
vide an increase in overall survival above statistical significance when compared to cis-
platin, was better tolerated and showed no signs of inducing nephrotoxicity [43]. 
The initial success of the acetato complexes satraplatin (14) and LA-12 (15) motivated 
researchers to investigate reduction pathways for Pt(IV) complexes having acetato 
ligands in the axial position. Reduction of 13C- and 15N-labelled cis,cis,trans-
[PtCl2(15NH3)(NH2R3)(OOC13CH3)2] (16*, R3 = H, isopropyl or cyclohexyl) was effected 
by different reducing agents like ascorbate, cytochrome c, NADH, or glutathione. Four 
reduction products were identified by monitoring the reactions using two-dimensional 
NMR spectroscopy and ESI-MS. In addition to the anticipated cisplatin analogue gener-
ated by loss of the axial acetato ligands (Scheme 2, red), additional products formed by 
elimination of one acetate and equatorial chloride (middle structures, in Scheme 2) or 
two chlorido ligands (structure at the right, Scheme 2). 
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Scheme 2. Possible products following reduction of isoptopically labeled 16*. 
 
These results challenge the commonly held supposition that, upon reduction, Pt(IV) 
compounds derived from cisplatin and related Pt(II) complexes, only release their axial 
ligands; this assumption might have to be reassessed for Pt(IV) derivatives carrying 
axial acetate groups [44]. 
The reduction of satraplatin (14) in extracts from three different cancer cell lines was 
monitored by 2D NMR spectroscopy. The cellular reduction rates followed the order 
A2780cisR > A2780 > HT-29, where HT-29 are colon cancer cells and A2780cisR is a 
cisplatin resistant cell line obtained from A2780 ovarian cancer cells by exposure to cis-
platin. Reduction of satraplatin was not performed by low molecular weight (MW) anti-
oxidants such as ascorbate and glutathione, but primarily by cellular components hav-
ing MW > 3000 [44]; the metalloproteins cytochrome c and hemoglobin in the presence 
of NADH were competent to reduce satraplatin [45]. The most rapid reduction occurred 
in A2780cisR cell extracts, perhaps due to its intrinsically elevated levels of glutathione 
[46]. 
Finally, a novel Pt(IV) complex [PtCl4(R42eddp)], where R4 = ethyl or n-propyl (17), con-
taining esters of ethylenediamine-N,N’-di-3-propionic acid (eddp) as bidentate ligands, 
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was described. Although the ligands themselves were not cytotoxic, the complexes had 
IC50 values at least ten times higher when compared to cisplatin. The cytotoxic activity 
was correlated with Pt uptake. The compound having R4 = n-propyl reacted with plas-
mid DNA as judged by gel electrophoresis studies [47]. 
 
3. Ruthenium 
The biological activity of Ru compounds was first recognized in the 1950s [48], and re-
ports of their anticancer activity appeared in the 1960s [49]. Several Ru-based com-
pounds show significant efficacy against various types of tumors in vivo [50] while hav-
ing lower toxicity than cisplatin in vitro [51, 52]. 
Of particular interest are Ru(II) arene compounds and bioreducible Ru(III) complexes 
with heterocyclic N-donor ligands. The only non-platinum transition metal compounds 
currently in clinical trials are two Ru coordination compounds of the latter class, 
[ImH][trans-RuCl4(DMSO)Im] (NAMI-A, 18, Figure 3) and [InH][trans-RuCl4In2] (KP1019, 
19) [53, 54]. The first Ru-based anticancer drug candidate in clinical trials was NAMI-A, 
followed by KP1019 in 2003. Both have successfully completed phase I. This achieve-
ment focused much attention on the medicinal properties of Ru compounds, reviews of 
which are available [55-60]. KP1019 is active against colon cancer [5]; NAMI-A has only 
low activity against primary tumors. NAMI-A is anti-angiogenic; its anti-invasive proper-
ties render it active against metastatic cancer. 
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Figure 3. Ru(III) compounds NAMI-A (18) and KP1019 (19). 
 
The mechanism of action of these Ru(III) compounds remains unknown and their in vivo 
chemistry is ambiguous [52]. Although Ru(III), like Pt(IV), can be reduced by ascorbate 
or glutathione under physiological conditions, the resulting Ru(II) complexes maintain 
their octahedral ligand set (Scheme 3) [54]. The biological target of Ru compounds has 
not been discovered. DNA adducts can be formed by both NAMI-A and KP1019. The 
resulting Ru-DNA adducts alter the duplex conformation [61]. KP1019 can unwind and 
bend DNA [62]. As for Pt(II) compounds, sulfur-containing biomolecules might bind to 
reduced Ru(II) species before they reach nuclear DNA. 
NAMI-A undergoes aquation reactions within minutes [54], whereas KP1019 is more 
stable, and better taken up by cells. About half of the intracellular Ru delivered in the 
form of KP1019 appears in the nucleus, which is quite high by comparison to other 
metal complexes; only 10% of cisplatin accumulates within the nucleus [63]. Ru com-
pounds not only target DNA but also proteins. KP1019 binds to transferrin [64] (Scheme 
3), an Fe(III) transport protein, and is released from the protein as Ru(II) after reduction 
by ascorbate or glutathione [6]. Interference with the Fe metabolism may also be an 
explanation for the anticancer activity of Ru(III) complexes [54]. 
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Scheme 3. Reduction pathways of Ru(III) compounds inside and outside the cell. 
 
The antitumor activity of Ru(III) compounds is postulated to depend on its reduction to 
Ru(II), since an increase in NAMI-A anti-metastatic activity occurs in the presence of 
biological reductants [55]. The more readily reduced Ru(III) complexes are more cyto-
toxic [65]. 
Transformations of Ru(III) complexes in mammalian cells have been monitored by 
XANES and EXAFS (X-ray absorption fine structure). It was concluded from these 
measurements that Ru(III) mainly binds to N-donors; however, gel filtration studies 
showed that Ru(III) was completely protein-bound [54]. A comparative study of a series 
of Ru(III) compounds using X-ray absorption spectroscopy (XAS) at the Cl K-edge and 
Ru L-edge revealed that the indazole ligand (In) in KP1019, a weak donor toward Ru, 
facilitates facile reduction [52]. As for Pt, the use of microprobe X-ray fluorescence 
might provide information about a potential Pt(IV)-like ‘activation by reduction’ [6] and 
clarify the role of transferrin in Ru(III) transport [53]. 
Ru(II)/Ru(III) redox chemistry has been studied thoroughly as an aspect of the mecha-
nism of action of Ru(III) prodrugs, recently reviewed [6]. The redox potentials of KP1019 
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and NAMI-A are 30 mV and 25 mV, respectively, vs. NHE. The redox potentials are tun-
able by modification of the azole ligand (In and Im, respectively) [6]. 
These redox potential values reveal that NAMI-A and KP1019 can be reduced by glu-
tathione and ascorbate under physiological conditions [66, 67]. As described in the in-
troduction, in addition to providing reducing agents, cancer cells also harbor a hypoxic 
environment that promotes reduction and subsequent reactivity [52]. Increased levels of 
Ru-DNA adducts occurred when the O2 partial pressure was low, indicating a greater 
amount of reduced, Ru(II), species [68]. 
Ru(III) phosphane complexes in which the metal is coordinated by two P,O,O-tridentate 
tris(o-anisyl) phosphane ligands are highly cytotoxic even in cisplatin-resistant cell lines 
[69]. Another construct involves NAMI A-type ligands conjugated through pyridyl or 
bipyridyl rings to yield Ru porphyrin conjugates (meso-4’-tetrapyridylporphyrin or meso-
(p-bipyridyl-phenyl)porphyrin). The number of Ru fragments attached to the porphyrins 
ranged from 1 to 4. Conjugation of porphyrins to the Ru center was an attempt to obtain 
additive antitumor effects originating from the phototoxic and tumor-localizing properties 
of the porphyrin together with the cytotoxic properties of Ru(III) [70]. Thus far, however, 
the compounds have not been tested in vitro or in vivo. 
An interesting conjugate was generated by coupling tamoxifen, a chemotherapeutic 
agent for patients with hormone-dependent breast cancer, with the organometallic Ru 
compound ruthenocene. This tamoxifen analog acts as an antiestrogen by competitive 
binding to the estrogen receptor in ER(+) breast cancer cells but not in ER(-) cells [71, 
72]. This result is in contrast to that for the Fe analog ferrocifen (20), which is active in 
both cell lines (vide infra). Since the structural differences between the Fe and Ru de-
rivative are marginal, the different redox properties of the metal ions may be responsible 
for the different patterns of activity [71]. 
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Although Os belongs to the same group in the periodic table as Fe and Ru, and thus 
should be also able to interact with biomolecules like proteins and nucleic acids, there 
are only a few studies on the biological activity of Os complexes. In comparison to 
analogous Ru compounds, Os complexes are more substitution inert and less prone to 
hydrolysis and interactions with nucleobases. Nevertheless, they also have potential as 
anticancer agents. By examining homologous Os compounds, one might even obtain 
useful information about the mechanism of action of Ru drugs [73-75]. 
Os(III)-NAMI-A-type compounds (LH)[trans-Os(III)Cl4(DMSO)(L)] with L = 1H-indazole 
(In), 1H-pyrazole, 1H-benzimidazole, 1H-imidazole (Im), 1H-1,2,4-triazole, and DMSO, 
are kinetically stable in aqueous solution, but exhibit similar or even higher cytotoxicity 
when compared with the analogous Ru compounds. For example, the indazole complex 
(L = In) had an IC50 value ca. ten times lower than that of the analogous Ru complex 
against HT-29 cells. Whereas hydrolysis is a prerequisite for the antimetastatic activity 
of NAMI-A in vivo, hydrolyzed species were not required for the in vitro antiproliferative 
activity of analogous Os(III) complexes [76, 77]. 
 
4. Iron, Cobalt, Copper 
Ferrocifen (20, Figure 4), like the corresponding Ru compound described above, is an 
organometallic derivative of the breast cancer drug tamoxifen. The ferrocene analog of 
hydroxytamoxifen, however, acts against both ER(+) and ER(-) human breast cancer 
cells, in contrast to the properties  of hydroxytamoxifen alone [62, 78]. This behavior is 
surprising since the latter cells lack an obvious molecular target for tamoxifen. It can be 
concluded that the antiproliferative effect stems from the antiestrogenic effect of the ta-
moxifen moiety plus the cytotoxicity of the redox-active ferrocenyl group. Ferrocene in-
terconverts inside the cell between oxidation states II and III, represented by ferrocene 
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and ferrocenium ions. The cytotoxicity is not caused by direct linkage to DNA but by 
formation of reactive oxygen species, which can damage DNA. 
Not only ferrocene derivatives containing Fe(II) but also ferrocenium derivatives con-
taining Fe(III) are cytotoxic, generating radicals and thus inducing DNA damage [79]. 
Pyrazole conjugated to ferrocene serves as a ligand (L) for Co, Ni, and Fe (M), forming 
ML2 and ML3 complexes, respectively. The ligand L and the three ML2 metal complexes 
induced cytotoxicity in MCF-7 breast cancer cells, with IC50 values ranging from 46 to 73 
µM; CoL2 exhibited the lowest IC50 value. As the redox potential increased, the toxicity 
of the metal complexes decreased [80]. 
 
Figure 4. Ferrocifen (20), a ferrocene derivative of tamoxifen, shown in blue. The third 
phenyl ring in tamoxifen is replaced by ferrocene. At the right is an Fe(III) complex (21) 
of the MMP inhibitor marimastat, depicted in blue. 
 
Marimastat was once considered to be a promising anticancer drug, acting by inhibiting 
MMPs (matrix metalloproteinases) overexpressed in cancer cells. Clinical development 
of marimastat was discontinued, however, due to the lack of therapeutic benefits in pa-
tients. The hydroxamic acid portion of the compound (blue in 21, Fig. 4) may have re-
acted avidly with metal ions in biological fluids, especially Fe(III) [81]. The potential for 
high metal affinity was intentionally exploited subsequently to generate a metal-carrying 
prodrug containing marimastat and other ligands. A tetradentate ligand set was pro-
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vided by salen (N,N-bis(salicylidene)-ethane-1,2-diimine) (cf. black part in 21). The oc-
tahedral Fe(III) marimastat salen complex (21) inhibited MMP activity in vitro approxi-
mately 30-times less efficiently than marimastat alone. Reduced inhibitory activity by Fe 
complexation of the hydroxamate functionality in marimastat and electrochemical data 
indicate a potential for developing a prodrug that might be activated bioreductively [82]. 
 
Co(III) has also been complexed by the hydroxamate moiety in marimastat, although 
the mechanism of action of such Co complexes is expected to differ from that of analo-
gous Fe(III) compounds, which are prone to generate reactive oxygen species. Instead, 
Co(III) can be reduced to Co(II) in biological environments, leading to the release of ma-
rimastat. Co(III) thus provides an inert framework for the transport of the MMP inhibitor, 
protecting the hydroxamate moiety prior to reaching the tumor. In this case, Co is not 
the active species itself but only a protecting group for an otherwise cytotoxic ligand. 
Similarly, Au(I) has been claimed to protect phosphane ligands from oxidation in Au 
complexes like auranofin used for the treatment of rheumatoid arthritis [83]. 
As in the Fe(III) complex, a tetradentate ligand, here tpa for tris(methylpyridyl)-amine, 
was combined with the hydroxamate to form the octahedral complex (22, Figure 5) [81, 
84]. Increased cytotoxicity was observed for the prodrug in comparison to the inhibitor 
alone. In an in vivo study free marimastat and its Co complex inhibited tumor growth in 
the mammary fat pad in mice; but only the Co complex showed a statistically relevant 
difference compared to the control group. The complex was 2-3 times more effective in 
reducing the tumor growth than the MMP inhibitor alone. Both marimastat and its Co 
complex, however, potentiated metastasis when compared to controls [81]. 
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Figure 5. Examples of Co(III) complexes with marimastat (22), N2O donor ligands (23), 
and acetylacetonato ligands (24). 
 
Co(III) complexes have reduction potentials in a range appropriate for being reduced 
under cellular conditions. In oxic cells, however, this is inhibited by the presence of oxy-
gen, which can compete with the complex for cellular reductants (redox cycling, 
Scheme 4) [85, 86]. Thus, in vivo, back-oxidation is prevented by the hypoxic nature of 
the tumor tissue [8]. Co(II) complexes generated from Co(III) prodrugs under hypoxic 
conditions can undergo substitution reactions to release their neutral ligands, ideally 
cytotoxic drugs, and to form hexaaqua species (Scheme 4). Ligands that have been 
studied thus far include nitrogen mustards [87-90], amines [91], quinolines, macrocyc-
lics [92], and tripodal ligands such as the one in the complex with marimastat (22) [4, 
81, 93]. 
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Scheme 4. Prodrug mechanism based on Co(III) complexes [1]. Redox cycling in the 
presence of oxygen and release of the active drug by substitution with aqua ligands un-
der hypoxic conditions. 
 
The redox behavior of Co(III) complexes with tridentate N2O donor ligands (as in 23) 
was investigated and reduction was found to occur at -1000 to -800 mV vs. NHE. The 
reduced, Co(II) forms of the compounds, inhibited cell growth of S. cerevisae more effi-
ciently than cisplatin (IC50 0.5 vs. 0.6 mM). The oxidized Co(III) forms were less cyto-
toxic than the reduced forms, indicating that the Co(III) species serve as prodrugs. A 
compound analogous to 23 in which the imidazoles were replaced by pyridines behaved 
similarly [94]. 
Nitrogen mustards are highly toxic due to their DNA cross-linking activity. In vivo they 
act unselectively, but can be deactivated by coordination to Co(III) and be released 
when reduction to Co(II) occurs in hypoxic tumor tissue, thereby reducing systemic tox-
icity [91, 95]. 
Some nitrogen mustard ligands showed hypoxic selectivity in tumor cells [95]. The Co 
complex [Co(Meacac)2(DCE)]+ (24, acac = acetylacetonate, DCE = N,N-bis(2-
chloroethyl)ethylenediamine) had 20-times greater activity against hypoxic than oxic 
cancer cells [96]. In a series of Co acac complexes, the redox potential was of impor-
tance for hypoxic selectivity. The optimal value was -305 mV vs. NHE [96]. For 24, hy-
poxic selectivity did not rely on redox cycling, i. e. reoxidation by O2 in oxic tissue, be-
cause reoxidation was too slow relative to ligand release [8, 85]. 
Co(III) cyclen complexes having azachloromethylbenzindoline in the coordination 
sphere can be reduced under hypoxic conditions to release this agent, a potent DNA 
minor groove alkylator [92]. 
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The chemistry of copper is attractive for the development of hypoxia selective drugs, 
because Cu has two oxidation states and the reduction potential in accessible within the 
cellular potential range [97]. 
As for Co(III), Cu(II) complexes can be reduced to form Cu(I) complexes of low stability 
to release an active ligand. Furthermore, radioactive isotopes of Cu can be used, pro-
viding the combination of radiation therapy with bioreduction. For this purpose, the tira-
pazamine ligand has been suggested as a hypoxic cytotoxin for use with radioactive 
Cu, combining the antitumor activity of the copper complex with its radioactivity, the Cu 
isotopes being 64Cu or 67Cu [98]. Radiolabelled 64Cu complexes carried by 
bis(thiocarbazone) and bis(salicylaldimine) ligands showed hypoxic selectivity against 
Chinese hamster ovary cancer cells [99]. 
Macrocyclic ligand systems used for Cu(II) include cyclen, cyclam and tacn. Complexes 
with nitrogen mustards based on these macrocyclics are cytotoxic against leukemia 
cells. The complexes were also cytotoxic in lung cancer cells selectively under hypoxic 
conditions. The stability of the reduced Cu(I) species was investigated by cyclic volt-
ammetry. Its redox chemistry is reversible, indicating that the reduced complex is sta-
ble. A Cu(II) complex with a mustard derivative of cyclen (1,4,7-tetraazacyclodecane, 
25, Figure 6) exhibited good aqueous stability and, in vitro a 24-fold increased cytotoxic-
ity under hypoxic conditions vs. oxic conditions. In aqueous solution, the redox behavior 
of the complex and its stability correlated well with hypoxia selectivity. The hypoxia se-
lectivity is thought to originate from redox cycling in oxic tissue, similar to the behavior 
of Co(III) prodrugs described above (Scheme 5). Complexes 26 and 27, derived from 
the macrocyclic ligands cyclam and tacn, respectively, release the ligand independent 
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of O2 partial pressure. This result indicates that bioreduction is less relevant for the lat-
ter systems, excluding their applications as prodrugs [89]. 
 
 
Figure 6. Examples of Cu(II) complexes for releasing nitrogen mustards based on cy-
clen (25), cyclam (26), and tacn (27). 
 
 
Scheme 5. Mechanism of prodrugs based on a Cu(II) nitrogen mustard cyclen complex 
(25). 
 
Copper diacetyl-bis(N4-methylthiosemicarbazone) is a promising compound for imaging 
hypoxic tissue based on PET using Cu radionuclides (60Cu, 61Cu, 62Cu, and 64Cu). A 
lower, i.e. more negative, reduction potential corresponded with increased selectivity of 
bioreduction and release of the ligand. Insight into the chemical and electronic proper-
ties underlying these previously observed structure-activity relationships was obtained 
recently by density functional theory (DFT) calculations [100]. 
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Cu(II) complexes with ligands based on 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide 
were developed to serve as selective hypoxic cytotoxins [101]. The complexes were 
evaluated under hypoxic and aerobic conditions in V79 cells. The complexes were 
equally low cytotoxic with the ligands under aerobic conditions, but more cytotoxic un-
der hypoxic conditions [102]. 
Quinoxaline-N1,N4-dioxides themselves are bioreductively activatable drugs. However, 
they exhibit low aqueous solubility and a short half life [103]. Their vanadyl complexes 
VOL2, with L being a quinoxaline-N1,N4-dioxide ligand, however, showed improved 
solubility and greater cytotoxicity than the free quinoxaline ligands, with high hypoxia 
selectivity [104]. 
Pyrophosphate-bridged binuclear complexes of Cu(II) display low nanomolar toxicity 
against adriamycin-resistant ovarian cancer cells. The complexes were tested in glu-
tathione assays to simulate cellular conditions. Cu(I) was formed in this reductive envi-
ronment and the system produced hydrogen peroxide from molecular oxygen, produc-
ing oxidative stress. The generation of oxidative stress might explain the high cytotoxic-
ity of this class of coordination compounds [105]. 
 
5. Nanobased Drug Delivery Systems 
Delivery systems can mediate transport of drug molecules to desired cell populations. 
Nanosized systems have been successfully applied in the last years, exploiting the 
EPR, or enhanced permeability and retention, effect as a means of passively targeting 
cancer tissue. A combination of metal prodrugs with nano-vehicles can be achieved 
either by surface tethering or encapsulation. Encapsulation protects the drug from deg-
radation before reaching cancer cells as well as the non-cancerous cells from the ef-
fects of the drug. Depending on the encapsulating material, controlled release of the 
	   27 
drug from the nanoparticles is possible. Peptides, antibodies, or aptamers can be at-
tached to the particle surface for active targeting of cancer tissue. In this section, we 
describe accumulation and active targeting as strategies for selectively delivering Pt(IV) 
prodrugs to cancer cells with the help of nanoparticle materials. Although more stable in 
the +IV oxidation state, Pt(IV) compounds are not impervious to degradation, as we 
have already discussed (section 2). Their combination with nanomaterials offers a 
promising opportunity to transport and protect these complexes from premature reduc-
tion in the blood stream. 
In one manifestation of this strategy, Pt(IV) was attached to single-walled carbon nano-
tubes (SWNT) for shuttling into cells (28, Figure 7). Such soluble functionalized SWNTs 
nanotubes cross the cell membrane by clathrin-dependent endocytosis. A substantial 
increase in cytotoxicity was obtained when compared to cisplatin and the untethered 
Pt(IV) complex. In one experiment, the SWNT “longboat” carried 65 Pt “passengers” as 
determined by atomic absorption spectroscopy [106]. For targeting of folate receptors 
on cancer cells, the Pt(IV) prodrug was also coupled to folate (29) by using a bisucci-
nate precursor, Pt(succ)2, Figure 7. One carboxyl group allowed coupling to folate via 
an amino linker, while the other allowed tethering to the aminated nanotube surface. 
The toxicity in cell lines expressing the folate receptor increased by up to 9-fold by 
comparison to cisplatin [107]. 
Gold nanoparticles have also been used as delivery systems for potentially therapeutic 
antisense oligonucleotides as well as Pt(IV) via covalent attachment (30). The nanopar-
ticles were functionalized with thiolated 28mer oligonucleotides containing a terminal 
dodecyl amine for conjugation. The Pt(IV) complex Pt(succ) (Figure 7) was tethered to 
the amino-functionalized DNA-Au-NP surface by forming an amide linkage [108]. The 
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constructs showed high levels of cellular uptake in different cell types and higher cyto-
toxicity when compared to cisplatin and the Pt(IV) precursor Pt(succ). 
Gold nanorods, on the other hand, are even more promising vehicles than gold 
nanoparticles due to longer circulation times when compared to the spherical particles. 
PEGylated nanorods were loaded with disuccinato Pt(IV) (Pt(succ)2, 31, Figure 7). Cyto-
toxicity in HeLa, A549, and MCF7 cells was increased by up to 66-fold when compared 
to cisplatin. Cytotoxicity could be correlated with Pt uptake as measured by ICP-MS 
[109]. 
Better protection of the Pt(IV) prodrug can potentially be provided by encapsulation into 
particles as opposed to tethering on their surface. Encapsulation protects the prodrug 
but also can ameliorate unwanted side-effects of the drug. Cisplatin itself shows only 
low loading efficiency (< 1 wt%) within the hydrophobic interiors of a polymer [110], but 
an increase of internalization into nanoparticles could be achieved by using a hydro-
phobic Pt(IV) compound instead. Nanoparticles based on poly(D,L-lactic-co-glycolic 
acid)-block-poly(ethylene glycol) (PLGA-b-PEG) combine hydrophobic PLGA for encap-
sulation and hydrophilic PEG for aqueous solubility [111]. A Pt(IV) compound carrying 
hydrophobic hexyl chains, Pt(hex)2 (Figure 7), was released from PLGA-PEG nanopar-
ticles in a controlled fashion over 60 h. The nanoparticles were taken up by cells by re-
ceptor-mediated endocytosis. Besides being designed for passive targeting (EPR), the 
nanoparticles were also expected to be guided to tumor tissue by active targeting.  For 
targeting prostate-specific membrane antigen (PSMA) over-expressed on prostate can-
cer cells, an A10 2-fluoropyrimidine RNA aptamer was coupled to the surface of the 
nanoparticle (32) [111]. This system showed better cytotoxic activity in vitro than cis-
platin and selectivity for the cells expressing the receptors targeted. In vivo studies with 
the PSMA-decorated Pt(IV) nanoparticle (32) demonstrated enhanced pharmacokinet-
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ics, biodistribution, and tolerability in rats and mice when compared to cisplatin. Efficacy 
in a PSMA-expressing LNCaP xenograft mouse model of prostate cancer was also 
higher. For obtaining the same degree of tumor volume reduction only 1/3 the dose of 
cisplatin was required [112]. 
Conjugation of dilevulinate Pt(IV) complexes Pt(levul)2 (Figure 7, levulinic acid = 4-
oxopentanoic acid) with a hydrazinated PEG-PLA diblock copolymer resulted in Pt(IV) 
loaded nanoparticles (33). The nanoparticles were of sub-100 nm size and exhibited a 
cisplatin loading yield of 1.1 wt%. Due to the acid-labile hydrazone bond, the system 
showed acid-responsive drug release kinetics. The ability to kill ovarian cancer cells 
was enhanced when compared to that of cisplatin [113]. 
A silica shell coating of coordination polymer nanoparticles based on Pt(succ)2 in-
creased half-release time for Pt by factor 9 - from 1 h for the uncoated Pt loaded poly-
mer to 9 h. Cytotoxicity was similar to that of cisplatin in breast cancer cells. Upon con-
jugation of integrin-targeting peptides c(RGDfK), in vitro toxicity against colon cancer 
cells could be slightly increased in comparison to cisplatin [114]. 
Lastly, ethoxysuccinato Pt(IV), the prodrug also used for coupling to SWNT in 28, was 
allowed to react postsynthetically with a dispersion of amino functionalized iron-
carboxylate nanoscale metal-organic frameworks. Once Pt was loaded into the frame-
work, the particles were coated with silica. The resulting material was then evaluated for 
its cytotoxicity in HT-29 cells and found to be slightly less cytotoxic than cisplatin. In or-
der to increase the cytotoxicity, the silica shell was functionalized with a silyl derivative 
of c(RGDfK) (34). As in the other examples described above, it was thereby armed for 
targeting integrins, over-expressed in many anigiogenic tumors. Cytotoxicity was thus 
increased, approaching that of cisplatin [115]. 
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Figure 7. Metal-based prodrugs based on carbon nanotubes (28, 29), Au nanoparticles 
and -rods (30, 31), polymeric nanoparticles made of PLGA-PEG (32) and PLA-PEG 
(33), and iron-carboxylate nanoscale metal-organic frameworks with silica coating (34). 
Loaded or coupled Pt(IV) compounds are shown below. As above (Figures 2, 4 and 5), 
targeting units are shown in blue. 
 
6. Conclusion 
Therapeutically active complexes of Pt and Ru demonstrate that metal complexes can 
play an important role in the treatment of cancer. It has been estimated that approxi-
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mately half the patients being treated for cancer today by chemotherapy receive a plati-
num compound. The motivation for seeking other metal complexes with therapeutic po-
tential and for developing new metal-based drugs comes especially from the success of 
the anticancer drug cisplatin. Also bioorganometallic chemistry, a relatively new branch 
of medicinal inorganic chemistry, has contributed to the field, as exemplified by the ta-
moxifen analog ferrocifen. 
In such complexes the tunable redox properties of the metal ion and ligand modifica-
tions can be exploited to control biological action. Ligand loss during reduction in hy-
poxic cancer tissue can activate metal complexes for binding to target molecules. Fur-
thermore, as for Co and Cu, the loss of the ligand in a reductive environment can also 
trigger the release of an active species, a molecule that would have shown systemic 
toxicity if not bound to the deactivating metal center. 
In the future, the design of metal drugs should focus on molecular targeting agents to 
provide greater selectivity and more effective drug administration. The activation by re-
duction strategy presented in this review is one strategy by which this goal can be ap-
proached. Metal complexes exhibiting targeting, both to cancer cells as well as to sub-
cellular targets therein, and selective activation properties can reduce side effects in 
therapy and potentially cure a wider range of cancers by circumventing resistance. The 
many opportunities that metal complexes have by comparison to organic molecules, 
especially their versatile redox chemistry, should be exploited for creating more efficient 
anticancer drugs. 
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Abbreviations 
acac, acetylacetonato; cyclam, 1,4,8,11-tetraazacyclotetradecane; cyclen, 1,4,7,10-
tetraazacyclododecane; DCE, N,N-bis(2-chloroethyl)ethylenediamine; eddp, ethyle-
nediamine-N,N’-di-3-propionic acid; en, ethylenediamine; EPR, enhanced permeability 
and retention; EXAFS, extended X-ray absorption fine structure; hex, hexanoato; 
HMGB, high-mobility group box; Im, 1H-imidazole; In, 1H-indazole; levul, levulinato (4-
oxopentanoato); MMP, matrix metalloproteinase; MW, molecular weight; NAMI-A, New 
Anti-tumor Metastasis Inhibitor, -A means that this is the first of a series; NHE, normal 
hydrogen electrode; PSMA, prostate-specific membrane antigen; QSAR, quantitative 
structure-activity relationship; salen, N,N’-bis(salicylidene)-ethane-1,2-diimine; SRIXE, 
synchrotron radiation-induced X-ray emission; succ, succinato (butanedioato); SWNT, 
single-walled nanotube; tacn, 1,4,7-triazacyclononane; tpa, tris(2-methylpyridyl)-amine; 
XANES, X-ray Absorption Near Edge Structure; XAS, X-ray absorption spectroscopy. 
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